PharmaCyte Biotech PMCB Institutional Ownership

Updated Oct 10, 2026

PharmaCyte Biotech, Inc. (NASDAQ:PMCB) had 28 institutional holders reporting a position on Form 13F for the quarter ended June 30, 2026.

• Collectively, these holders controlled 7.10% of PharmaCyte Biotech's outstanding shares in Q2 2026, down from 9.01% in Q1 2026.
• Total holdings of PMCB shares fell 21.17% from Q1 2026, and the holder count rose 27.27% from Q2 2025.
• Of these 28 holders, 8 added to their positions, 10 reduced their stakes and 10 left their positions unchanged.
• In total, institutional investors held 762.76K shares of PharmaCyte Biotech at the end of Q2 2026, down 204.82K from the prior quarter and up 185.96K from a year earlier.
• As of June 30, 2026, the biggest holder of PharmaCyte Biotech was Citadel Advisors LLC with 283.38K shares, or 2.64% of shares outstanding.
• The largest position increases in PMCB for Q2 2026 were by Jane Street Group, LLC (+18.53K shares), Commonwealth Equity Services, LLC (+9.94K shares), Vanguard Capital Management LLC (+5.31K shares), SBI Securities Co., Ltd. (+3 shares) and Osaic Holdings, Inc. (+1 share).
• Among holders that kept a stake in PharmaCyte Biotech, the biggest sellers in Q2 2026 were Citadel Advisors LLC (-76.17K shares), Geode Capital Management, LLC (-71.41K shares), Renaissance Technologies LLC (-18.51K shares), XTX Topco Ltd (-18.18K shares) and HRT Financial LP (-9.29K shares).
• Business Quant data shows the 10 biggest positions in PharmaCyte Biotech as of Q2 2026 were held by Citadel Advisors LLC (283.38K shares), Geode Capital Management, LLC (124.25K shares), Vanguard Capital Management LLC (56.78K shares), Susquehanna International Group, LLP (44.85K shares), Renaissance Technologies LLC (37.99K shares), XTX Topco Ltd (34.18K shares), Northern Trust Corp (32.62K shares), Jane Street Group, LLC (30.06K shares), Schonfeld Strategic Advisors LLC (26.93K shares) and Vanguard Fiduciary Trust Co (23.45K shares).